213 related articles for article (PubMed ID: 20150450)
1. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
[TBL] [Abstract][Full Text] [Related]
2. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
[TBL] [Abstract][Full Text] [Related]
3. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
[TBL] [Abstract][Full Text] [Related]
4. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
5. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.
Arns W; Sommerer C; Glander P; Ariatabar T; Porstner M; May C; Paulus EM; Shipkova M; Fischer W; Liefeldt L; Hackenberg R; Schemmer P; Domhan S; Zeier M; Budde K
Clin Nephrol; 2013 Jun; 79(6):421-31. PubMed ID: 23611518
[TBL] [Abstract][Full Text] [Related]
7. Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients.
Budde K; Tedesco-Silva H; Arns W; Shoker A; Zeier M; Klinger M; Rosales B; Walker R; Prestele H; Vaidya S; Kuypers D
Transplantation; 2011 Aug; 92(3):321-7. PubMed ID: 21694664
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.
Bremer S; Vethe NT; Rootwelt H; Jørgensen PF; Stenstrøm J; Holdaas H; Midtvedt K; Bergan S
J Transl Med; 2009 Jul; 7():64. PubMed ID: 19635156
[TBL] [Abstract][Full Text] [Related]
9. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study.
Zhang H; Liu L; Li J; Fu Q; Wan J; Deng R; Wang H; Liao J; Deng W; Deng S; Chen L; Wang C
Int J Clin Pract; 2016 Jun; 70 Suppl 185():22-30. PubMed ID: 27198001
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
Pons B; Delavenne X; Mehdi M; Maillard N; Sauron C; Berthoux F; Alamartine E; Basset T; Mariat C
Clin Nephrol; 2012 Jun; 77(6):425-31. PubMed ID: 22595383
[TBL] [Abstract][Full Text] [Related]
12. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
[TBL] [Abstract][Full Text] [Related]
16. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
[TBL] [Abstract][Full Text] [Related]
17. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients.
Sommerer C; Glander P; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Liefeldt L; Hackenberg R; Schmidt J; Zeier M; Budde K
Transplantation; 2011 Apr; 91(7):779-85. PubMed ID: 21297553
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
